Advancing drug discovery for schizophrenia
1Semel Institute for Neuroscience at the University of California, Los Angeles; and David Geffen School of Medicine, Los Angeles, California.
2University of North Carolina School of Medicine, Department of Pharmacology, Chapel Hill, North Carolina.
3University of North Carolina, Department of Genetics, Chapel Hill, North Carolina.
4Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
5Mount Sinai Medical Center, New York, New York.
6University of California, San Diego, La Jolla, California.
7Clinical Brain Disorders Branch, Genes, Cognition, and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
8Department of Psychiatry, Columbia University, New York, New York.
9New York State Psychiatric Institute, New York, New York.
10University of Illinois at Chicago, Chicago, Illinois.
11Research Institute and Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, Massachusetts.
12University of Maryland School of Medicine, Baltimore, Maryland.
13Vanderbilt Program in Drug Discovery, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee.
14Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
15Pfizer Neuroscience, Groton, Connecticut.
16Yale University School of Medicine, New Haven, Connecticut.
17Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania.
18Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
19Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland.
20Department of Cell Biology, Duke University Medical Center, Durham, North Carolina.
21Centre for Addiction and Mental Health, Departments of Medicine and Pharmacology, University of Toronto, Toronto, Ontario, Canada.
22Pfizer Neuroscience, Groton, Connecticut; and University of North Carolina School of Medicine, Department of Pharmacology, Chapel Hill, North Carolina.
23Schizophrenia Research Forum